

ACSAP 2017 Book 1 (Oncologic/Hematologic Care)

Total Available Hours: 17.5

BCACP test deadline: 11:59 p.m. (Central) on May 15, 2017.

ACPE test deadline: 11:59 p.m. (Central) on September 14, 2020.

Oncologic Care I (Module 1) – Credit Hours: 4.0**Chapter: Cancer Screening and Prevention****Learning Objectives**

1. Evaluate the risks and benefits of cancer screening and prevention.
2. Assess the differences in cancer prevention therapies for patients with normal- and high-risk breast cancer.
3. Construct a cancer prevention plan for a patient at risk of breast, colorectal, human papillomavirus–related, or prostate cancer.
4. Distinguish between cancer screening guideline recommendations for breast, cervical, colorectal, lung, and prostate cancers.
5. Design an appropriate cancer-screening plan for an individual patient according to cancer-screening guidelines and individual risk factors.

Chapter: Lung Cancer**Learning Objectives**

1. Design a treatment plan for a patient with small cell lung cancer.
2. Evaluate the role of mutational analysis in patients with non-small cell lung cancer (NSCLC).
3. Design a treatment plan for a patient with NSCLC.
4. Develop a treatment algorithm for a patient with metastatic NSCLC with epidermal growth factor receptor mutation–positive disease, anaplastic lymphoma kinase rearrangement, or ROS proto-oncogene 1 rearrangement.
5. Assess the impact of adding vascular endothelial growth factor receptor inhibitors in NSCLC.
6. Examine the role of immunotherapy in the treatment of metastatic NSCLC.

Oncologic Care II (Module 2) – Credit Hours: 4.0**Chapter: Toxicities of Oral Targeted Chemotherapy****Learning Objectives**

1. Distinguish between the epidermal growth factor receptor (EGFR)/MAPK/ERK kinase (MEK) inhibitor rash and the hand-foot skin reaction, given symptomatology, and design appropriate prevention and management regimens.
2. Evaluate preventive strategies for agents associated with photosensitivity.
3. For the patient taking oral targeted treatment, assess the risk of QTc prolongation given concomitant medications and comorbidities, and devise a risk management plan.
4. Develop monitoring and treatment plans for vascular endothelial growth factor inhibitor–induced hypertension and left ventricular ejection fraction dysfunction.

5. Construct monitoring plans, treatment goals, and therapy plans for hypothyroidism, hyperlipidemia, and hyperglycemia associated with oral targeted cancer treatment.

Chapter: Melanoma

Learning Objectives

1. Demonstrate an understanding of the epidemiology of melanoma skin cancers and the role of screening for the prevention of skin cancer.
2. Evaluate the role of immunotherapy in the adjuvant treatment of melanoma.
3. Evaluate the role of ipilimumab, nivolumab, and pembrolizumab in the treatment of metastatic melanoma.
4. Justify the role of genetic analysis in treatment selection with BRAF/MEK tyrosine kinase inhibitors.
5. Distinguish the role of oral BRAF inhibitor therapy in the treatment of skin cancer.
6. Design a pharmacotherapy plan – including monitoring parameters, side effect management, and, where applicable, oncolytic virus therapy – for the patient with metastatic melanoma.

Oncologic Care III (Module 3) – Credit Hours: 4.5

Chapter: Cancer Survivorship

Learning Objectives

1. Compose an appropriate management plan for a cancer survivor with treatment-induced cardiotoxicity.
2. Evaluate the pharmacologic and nonpharmacologic options for managing peripheral and central neurotoxicities.
3. Develop a treatment plan to manage cancer-related fatigue and sleep disorders in cancer survivors.
4. Compose recommendations associated with sexual health and infertility in cancer survivors.
5. Apply screening and lifestyle recommendations to individualize care in cancer survivors.
6. Justify the importance of implementing a survivorship care plan.

Chapter: Vaccination in the Patient with Immunocompromise

Learning Objectives

1. Distinguish between innate, adaptive, cellular, and humoral immunity, including the role of and the cells involved in each.
2. Assess the impact of diseases and therapies on immunity.
3. Develop a risk-benefit tool to determine the vaccination plan for a particular patient.
4. Using current data and the available vaccines, justify the optimal vaccination product and timing for the patient with immunocompromise.
5. Evaluate opportunities to improve vaccination rates and emerging trends in vaccinations in the patient with immunocompromise.

Hematologic Care I (Module 4) – Credit Hours: 5.0

Chapter: Chronic Lymphocytic Leukemia

Learning Objectives

1. Devise appropriate chronic lymphocytic leukemia (CLL) treatments on the basis of patient characteristics.
2. Develop management plans for adverse effects and drug interactions of drug therapy for CLL.
3. Design an antimicrobial prophylaxis regimen based on the drug therapy used for CLL.
4. Construct an appropriate management plan for hepatitis B reactivation with CLL drug therapy.
5. Detect or manage complications commonly experienced by patients with CLL.

Chapter: Multiple Myeloma

Learning Objectives

1. Demonstrate knowledge of the pathogenesis and risk factors for multiple myeloma (MM) as well as the clinical presentation of the disease.
2. Distinguish the different staging systems and the response criteria used in MM.
3. Evaluate patients with myeloma and design the appropriate treatment options, including new therapies.
4. Justify supportive care for issues including bone disease, thromboembolism, neuropathy, and prevention of infection associated with myeloma disease and treatment.